NP-101 plus nivolumab and ipilimumab demonstrated activity in patients with metastatic EP-NECs that were refractory to chemotherapy.

rhIL‑7-hyFc was not associated with improved survival in the overall cohort but was associated with improved survival in older patients. Adding rhIL‑7-hyFc, a long-acting IL-7, to treatment with ...

Paltusotine can alleviate symptoms of carcinoid syndrome in patients with neuroendocrine tumors, a phase 2 study suggests.

The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.

Adding TTFields to first-line treatment with temozolomide and radiotherapy improved progression-free survival in patients with glioblastoma.

More than three-quarters of evaluable patients had a tumor-associated antigen-specific immune response. CVGBM, an investigational cancer vaccine, induced immune responses in more than three-quarters ...

In its accelerated approval decisions of new cancer drugs, the FDA might be underestimating the willingness of some patients ...

A CXB boost continues to provide an organ preservation benefit at 5 years, though there is some local regrowth after 3 years, ...

Combination treatment with retifanlimab, bevacizumab, and hypofractionated radiotherapy — with or without epacadostat — ...

The disease control rate was 92%, and the median progression-free survival was 13.7 months. Treatment with 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and pembrolizumab appeared ...

Study results “provide strong support for integrating symptom screening and care pathways into routine clinical care,” according to researchers ...